Copy Link Print Information

XAV-939

190 Cited Publications
Customer Review

Based on 190 publication(s) in Google Scholar

XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation.

For research use only. We do not sell to patients.

  • Purity: 99.80%
  • CAS No.: 284028-89-3
  • Formula: C14H11F3N2OS
  • Molecular Weight:312.31
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • XAV-939 Chemical Structure
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • XAV-939 Chemical Structure
    XAV-939 Chemical Structure
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
CAS No.: 284028-89-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) XAV-939

More
Customer Validation & Images
2D/3D Cell Culture and DifferentiationIFWB
  • WB
  • 2D/3D Cell Culture and Differentiation
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All PARP Isoforms

More
Keywords
100 mg
Get Quote In-stock
Please select quantity
Price: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • XAV-939 Chemical Structure
    XAV-939 Chemical Structure
    1/16
  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Jun 7;15(6):e17101. [Abstract]

    Customer Validation
     XAV939 (20 μM; 3 days) restores the expression of Homer1, PSD95, and GluR1 in Shank3 knockout (KO) human neurons.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jan;601(7894):600-605. [Abstract]

    Customer Validation
     Upon exposure to lysophosphatidic acid (LPA) (a Hippo pathway inhibitor), A83-01 (an inhibitor of TGFβ family receptors) and PD0325901 (an ERK inhibitor) in a chemically defined medium containing the STAT activator leukaemia inhibitory factor (LIF) and Y-27632 (a ROCK inhibitor) (10 µM, 7 days),blastocyst-like structures formed efficiently from naive PSCs.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jan;601(7894):600-605. [Abstract]

    Customer Validation
     Upon exposure to lysophosphatidic acid (LPA) (a Hippo pathway inhibitor), A83-01 (an inhibitor of TGFβ family receptors) and PD0325901 (an ERK inhibitor) in a chemically defined medium containing the STAT activator leukaemia inhibitory factor (LIF) and Y-27632 (a ROCK inhibitor) (10 µM, 7 days), blastocyst-like structures formed efficiently from naive PSCs. trophectoderm (TE) cell analogues (identified as GATA2+GATA3+CDX2+TROP2+) formed, proliferated, and established adherens junctions (marked by CDH1), apical-basal polarity (indicated by aPKC) and tight junctions (marked by ZO-1).

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2023 Jan 1:249:114410. [Abstract]

    Customer Validation
     XAV-939 (5 μM) significantly decreases the expression level of β-catenin in A549 cells.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2020 Sep 1;319(3):F458-F468. [Abstract]

    Customer Validation
     Representative Western blot showing FN protein abundance in HMCs cultured in media containing NG or HG in the absence or presence of liraglutide (100 nM) or DMSO (1:1000) or XAV-939 (5 μM) for 24 h.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 18;9(2):27. [Abstract]

    Customer Validation
     The cellular locations of β-catenin are detected by western blot. GAPDH, Histone H3, and ATP1A1 are used to normalize protein expression in total lysates and nuclear and membrane fractions, respectively. SGC-7901 cells with PCDHGA9 overexpression or vector control cells are grown in media with or without 10 μg/mL inhibitor of β-catenin (XAV-939).

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 21:9:660. [Abstract]

    Customer Validation
     By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (CP-358774), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Anticancer Drugs. 2018 Mar;29(3):208-215. [Abstract]

    Customer Validation
     SUM159 sphereforming cells are treated with 15 μM XAV-939 for 7 days, and the protein expression levels of breast cancer stem cells (CSCs) markers are detected by western blotting.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Anticancer Drugs. 2018 Mar;29(3):208-215. [Abstract]

    Customer Validation
     SUM159 sphere-forming cells are treated with GDC-0449 (15 μM), a Smoothened (Smo) inhibitor for 7 days, and the protein expression levels of breast cancer stem cells (CSCs) play markers are detected by western blotting.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067. [Abstract]

    Customer Validation
     Western blot analysis and alizarin red staining of hDFSCs transfected by EZH2-siRNA and treated by XAV-939. DMSO is used as a vehicle control.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Biomed Res Int. 2017:2017:1972608. [Abstract]

    Customer Validation
     To investigate the roles of β-catenin, XAV939 (β-catenin inhibitor) was added to MNT group. Total protein is used to observe the expression of Nrf2 and LC3.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1898-906. [Abstract]

    Customer Validation
     Analysis of the in vitro role of the Wnt/β–catenin pathway in the regulation of AQP2 expression in response to sPRR-His treatment. Effect of XAV on sPRR-His-induced AQP2 expression (n = 6 per group).

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2016;39(1):360-70. [Abstract]

    Customer Validation
     EGF upregulates the expression of follicle-regulatory genes via Wnt/β-catenin signaling pathway. (A) The mRNA and (B, C) the protein levels of Survivin, Msx2 and SGK3 in the ORS cells with EGF treatment/overexpression and/or XAV-939 treatment.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Comp Biochem Phys B. 2016 Jan;191:155-62. [Abstract]

    Customer Validation
     The protein expression of Wnt10b and p-GSK-3β is significantly induced by LiCl treatment (A and B). Nevertheless, XAV939 treatment significantly inhibits the protein expression of p-GSK-3β (B). Moreover, the protein expression of p-β-catenin is significantly inhibited by LiCl treatment, but significantly induced by XAV939 treatment (C).

  • XAV-939